X4 Pharmaceuticals Inc. (NASDAQ:XFOR) currently has a daily average trading volume of 830.90K but it saw 371406 shares traded on Wednesday. With a market cap of 115.30M USD, stock’s current market price of $1.73 came falling about -2.81 while comparing to the previous closing price of $1.78. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.76 and as low as $0.86. In the recent trading on the day, stock has struck highest price mark of $1.81 while lowest mark touched by it was $1.68.
Taking a look at 20-day trading activity of X4 Pharmaceuticals Inc. (XFOR) gives us an average price of $1.8585, while its current price level is -63.62% below from 52-week high level whereas it is 101.28% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.7327 while that of 200 days or SMA-200 reads an average of $1.4546. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.54% during that period while stretching the period over a month that decreases to 7.64%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 44.89 which implies that the stock is in neutral territory.
X4 Pharmaceuticals Inc. (XFOR)’s stock is currently under the radar of 6 analysts who are in consensus at a 12-month price target range of between $3.50 and $7.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $3.50 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $7.00. Average price target assigned by them is $5.60 which highlights an upside potential of 69.11% for the stock over that period. And to attain the median price target of $6.00 assigned by those analysts, stock has to add about 71.17% of value to its current levels.
Data by FactSet Research shows that 6 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 6 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Oppenheimer which initiated the stock as “Outperform” in its note to investors issued on December 23, 2019, recommending a price target of $20 for it. Citigroup issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $16 and $20.
Over the week, XFOR’s stock price is moving -3.89% down while it is -13.07% when we observe its performance for the past one month. Year-to-date it is -24.45% down and over the past year, the stock is showing a downside performance of -61.56%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$0.6 beat the consensus estimate of -$0.64 for the same. For XFOR, analysts are forecasting an EPS-growth rate of 52.40% for current year and estimate for EPS growth in next year is 24.70%.
Currently, X4 Pharmaceuticals Inc.’s total number of outstanding shares is 83.21M with 1.01% of that held by the insiders while 37.82% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -200.40%. Stock’s beta reads 0.41. Stock has a price to book (P/B) ratio of 2.34. Its return on asset (ROA) is -100.40% on average.
A filing at the U.S. Securities and Exchange Commission revealed that AXA Framlington Biotech Fund came shrinking its share ownership by 2.11% in the X4 Pharmaceuticals Inc. (XFOR) increasing its stake to 5.72% with control over 81280.0 shares in the company. In the most recent quarter, FCP Medical – BioHealth came rising its stake by 82.55% in the company and now holds 0.59 million or 0.86% of the company’s stake having worth of about 1.13 million.